
|Articles|June 1, 2001
- Pharmaceutical Executive-06-01-2001
- Volume 0
- Issue 0
Rx-to-OTC: Unwanted Attention
Author(s)Kevin Gopal
Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.
Advertisement
Articles in this issue
almost 25 years ago
Industry Under Investigationalmost 25 years ago
Emotion - The New Brand Integratoralmost 25 years ago
For Love of the Gamealmost 25 years ago
Field of Dreamsalmost 25 years ago
Workshop: Access Optionsalmost 25 years ago
Emotion - The New Brand Integratoralmost 25 years ago
Emotion - Biotech Renaissance Manalmost 25 years ago
Relocation: Coming to Americaalmost 25 years ago
Stocks: Catching the Market Bluesalmost 25 years ago
Gathering LightNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
What Governance Resets Should Pharma Companies Take in Response to AI?
3
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
4
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
5




